Free Trial
→ The only 5 stocks that matter (From TradeSmith) (Ad)tc pixel
NASDAQ:BMRA

Biomerica Q3 2025 Earnings Results & Report

Biomerica logo
$1.83 -0.06 (-3.17%)
As of 10/9/2026 04:00 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Biomerica reported Q3 2025 earnings on April 14, 2025. The company reported EPS of -$0.48, while revenue was $1.12 million.

Research:ProfileEarnings HistoryForecast

Earnings Announcement Details

Quarter
Q3 2025
Report Date
Time
After Market Closes

Biomerica EPS Results

Actual EPS
-$0.48
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Biomerica Revenue Results

Actual Revenue
$1.12 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Upcoming Earnings

Biomerica's next earnings date is estimated for Wednesday, October 21, 2026, based on past reporting schedules.

Conference Call Resources

Biomerica Q3 2025 Earnings FAQ

Biomerica (NASDAQ:BMRA) reported earnings of -$0.48 per share for Q3 2025. The report was announced on Monday, April 14, 2025.

Biomerica reported revenue of $1.12 million for Q3 2025.

Biomerica's next earnings date is estimated for Wednesday, October 21, 2026. MarketBeat tracks confirmed and estimated earnings dates for Biomerica on the company's earnings history page.

Biomerica Earnings Headlines

Biomerica (NASDAQ:BMRA) Shares Break Below Two Hundred Day Moving Average - Should You Sell?
October 9 at 3:23 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31102156
Biomerica (NASDAQ:BMRA) versus Boston Scientific (NYSE:BSX) Head-To-Head Contrast
October 2, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31077639
Here’s Why Trump Won’t End The Iran War
Trump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. One day it's a ceasefire, the next it's bombs again. The back and forth may be masking a bigger story most investors are missing. See the real reason this conflict may never fully end.tc pixel
October 10 at 1:00 AM  |  Banyan Hill Publishing (Ad)
Biomerica, Inc. (NASDAQ:BMRA) Sees Significant Decline in Short Interest
October 1, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31074147
Biomerica Files $250 Million Mixed Shelf
September 27, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/biomerica-files-250-million-mixed-193005577.html
Biomerica Posts Narrower Q4 Loss On Higher Sales; Stock Down
September 2, 2026  |  rttnews.comhttps://www.rttnews.com/3687774/biomerica-posts-narrower-q4-loss-on-higher-sales-stock-down.aspx
See More Biomerica Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Biomerica? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Biomerica and other key companies, straight to your email.

About Biomerica

Biomerica (NASDAQ:BMRA) is a medical diagnostics company that develops and commercializes products designed to help diagnose and manage gastrointestinal and other health conditions. The company focuses on tests and related solutions intended to support more personalized treatment decisions.

Biomerica’s best-known product platform is inFoods, which uses blood-based testing to identify foods that may contribute to symptoms associated with gastrointestinal disorders. The company has emphasized inFoods IBS, a diagnostic-guided dietary management solution for people with irritable bowel syndrome, pairing test results with individualized food recommendations.

Biomerica also has developed and marketed diagnostic products for conditions including Helicobacter pylori infection, allergies and respiratory illnesses. Its products have been distributed through healthcare providers and commercial partners in the United States and select international markets. The company is headquartered in Irvine, California, and has been led by Chief Executive Officer Zackary Irani.

View Biomerica Profile
Earnings Tools